Non-toxic metabolic management of metastatic cancer in VM mice: Novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Poff, A M ^a   Ward, N ^a   Seyfried, T N ^b   Arnold, P ^c   D'Agostino, D P ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b BOSTON COLLEGE   (United States)

^c Savind Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; KETONE; OXYGEN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DIET SUPPLEMENTATION; GLUCOSE BLOOD LEVEL; HYPERBARIC OXYGEN; KETOGENIC DIET; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; SURVIVAL TIME; ANIMAL; EXPERIMENTAL NEOPLASM; HYPERBARIC OXYGEN THERAPY; NEOPLASM METASTASIS; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; HYPERBARIC OXYGENATION; KETOGENIC DIET; KETONES; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL;

EID: 84936976775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127407     Document Type: Article

References (105)

1. Bayley J-P, Devilee P. The Warburg effect in 2012. Current opinion in oncology. 2012; 24:62-9. doi: 10.1097/CCO.0b013e32834deb9e PMID: 22123234
2. Seyfried TN. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Hoboken, NJ: John Wiley & Sons, In.; 2012. 421 p.
3. Gillies R, Robey I, Gatenby R. Causes and consequences of increased glucose metabolism of cancers. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2008; 49 Suppl 2. doi: 10.2967/jnumed.107.047258
4. Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des. 2012; 18(10):1319-30. Epub 2012/03/01. PMID: 22360558.
5. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014; 35(3):515-27. Epub 2013/12/18. doi: 10.1093/carcin/bgt480 PMID: 24343361; PubMed Central PMCID: PMC3941741.
6. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia. 2005; 7(4):324-30. Epub 2005/06/22. PMID: 15967109; PubMed Central PMCID: PMC1501147.
7. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985; 62(6):816-22. Epub 1985/06/01. doi: 10.3171/jns.1985.62.6.0816 PMID: 2987440.
8. Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc. 1995; 95(6):693-7. Epub 1995/06/01. doi: 10.1016/S0002-8223(95)00189-1 PMID: 7759747.
9. Poff AM, Ari C, Seyfried TN, D'Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013; 8(6):e65522. Epub 2013/06/12. doi: 10.1371/journal.pone.0065522 PMID: 23755243; PubMed Central PMCID: PMC3673985.
10. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and mediumchain triglycerides. BMC Cancer. 2008; 8:122. doi: 10.1186/1471-2407-8-122 PMID: 18447912
11. Schmidt M, Pfetzer N, Schwab M, Strauss I, Ka¨mmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond). 2011; 8(1):54. doi: 10.1186/1743-7075-8-54
12. Masko E, Thomas J, Antonelli J, Lloyd J, Phillips T, Poulton S, et al. Low-carbohydrate diets and prostate cancer: how low is "low enough"? Cancer prevention research (Philadelphia, Pa). 2010; 3(9):1124-31. doi: 10.1158/1940-6207.capr-10-0071 PMID: 20716631
13. Stafford P, Abdelwahab M, Kim DY, Preul M, Rho J, Scheck A. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010; 7:74. doi: 10.1186/1743-7075-7-74 PMID: 20831808
14. Tisdale MJ, Brennan RA. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. Br J Cancer. 1988; 58(5):580-3. Epub 1988/11/01. PMID: 3219268; PubMed Central PMCID: PMC2246820.
15. Tisdale MJ, Brennan RA, Fearon KC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer. 1987; 56(1):39-43. Epub 1987/07/01. PMID: 3620317; PubMed Central PMCID: PMC2001676.
16. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond). 2007; 4:5. Epub 2007/02/23. doi: 10.1186/1743-7075-4-5 PMID: 17313687; PubMed Central PMCID: PMC1819381.
17. Fine E, Segal-Isaacson C, Feinman R, Herszkopf S, Romano M, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012; 28(10):1028-35. doi: 10.1016/j.nut.2012.05.001 PMID: 22840388
18. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta. 2013; 1831(10):1499-508. Epub 2013/03/09. doi: 10.1016/j.bbalip.2013.02.008 PMID: 23470257; PubMed Central PMCID: PMC3766377.
19. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002; 3(9):565-74. Epub 2002/09/10. PMID: 12217794.
20. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond). 2010; 7:33. Epub 2010/04/24. doi: 10.1186/1743-7075-7-33 PMID: 20412570; PubMed Central PMCID: PMC2874558.
21. Seyfried TN, Flores R, Poff AM, D'Agostino DP, Mukherjee P. Metabolic therapy: a new paradigm for managing malignant brain cancer. Cancer Lett. 2015; 356(2 Pt A):289-300. doi: 10.1016/j.canlet.2014.07.015 PMID: 25069036.
22. Poff AM, Ari C, Arnold P, Seyfried TN, D'Agostino DP. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. International journal of cancer 2014. Epub 2014/03/13. doi: 10.1002/ijc.28809 PMID: 24615175.
23. Fine EJ, Miller A, Quadros EV, Sequeira JM, Feinman RD. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. Cancer Cell Int. 2009; 9:14. Epub 2009/06/02. doi: 10.1186/1475-2867-9-14 PMID: 19480693; PubMed Central PMCID: PMC2694762.
24. Seyfried T, Kiebish M, Marsh J, Shelton L, Huysentruyt L, Mukherjee P. Metabolic management of brain cancer. Biochim Biophys Acta. 2011; 1807:577-671. doi: 10.1016/j.bbabio.2010.08.009 PMID: 20804725
25. Barbara AM, Nicholas P, Allan MR, Robert AJC. THE INHIBITION OF MALIGNANT CELL GROWTH BY KETONE BODIES. Australian Journal of Experimental Biology and Medical Science. 1979; 57. doi: 10.1038/icb.1979.54
26. Chang HT, Olson LK, Schwartz KA. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr Metab (Lond). 2013; 10(1):47. Epub 2013/07/09. doi: 10.1186/1743-7075-10-47 PMID: 23829383; PubMed Central PMCID: PMC3707813.
27. Tisdale M, Brennan R. Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br J Cancer. 1983; 47(2):293-7. doi: 10.1038/bjc.1983.38 PMID: 6130780
28. Maurer G, Brucker D, Ba¨hr O, Harter P, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011; 11:315. doi: 10.1186/1471-2407-11-315 PMID: 21791085
29. Lyssiotis C, Heiden M, Muñoz-Pinedo C, Emerling B. Emerging concepts: linking hypoxic signaling and cancer metabolism. Cell death & disease. 2012; 3. doi: 10.1038/cddis.2012.41
30. Lum J, Bui T, Gruber M, Gordan J, DeBerardinis R, Covello K, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes & development. 2007; 21(9):1037-49. doi: 10.1101/gad.1529107
31. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic acids research. 2009; 37(14):4587-602. Epub 2009/06/06. doi: 10.1093/nar/gkp425 PMID: 19491311; PubMed Central PMCID: PMC2724271.
32. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009; 9(9):1084-101. Epub 2009/08/20. PMID: 19689405.
33. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol. 2007; 22(5):559-72. Epub 2007/03/03. PMID: 17330811.
34. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013; 123(9):3664-71. Epub 2013/09/04. doi: 10.1172/JCI67230 PMID: 23999440; PubMed Central PMCID: PMC3754249.
35. Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods in enzymology. 2004; 381:335-54. doi: 10.1016/s0076-6879(04)81023-1 PMID: 15063685
36. Semenza G. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Seminars in cancer biology. 2009; 19:12-8. doi: 10.1016/j.semcancer.2008.11.009 PMID: 19114105
37. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochemical pharmacology. 2013; 85(9):1219-26. Epub 2013/02/26. doi: 10.1016/j.bcp.2013.02.017 PMID: 23435357.
38. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2011; 14(3):191-201. Epub 2011/04/07. doi: 10.1016/j.drup.2011.03.001 PMID: 21466972.
39. Ghattass K, Assah R, El-Sabban M, Gali-Muhtasib H. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy. Curr Cancer Drug Targets. 2013; 13(6):670-85. Epub 2013/05/22. PMID: 23687923.
40. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Medical oncology (Northwood, London, England). 2001; 18(4):243-59. doi: 10.1385/mo:18:4:243 PMID: 11918451
41. Gray L, Conger A, Ebert M, Hornsey S, Scott O. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British journal of radiology. 1953; 26(312):638-48. doi: 10.1259/0007-1285-26-312-638 PMID: 13106296
42. Hoogsteen I, Marres H, van der Kogel A, Kaanders J. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clinical oncology (Royal College of Radiologists (Great Britain)). 2007; 19(6):385-96. doi: 10.1016/j.clon.2007.03.001
43. Beppu T, Kamada K, Yoshida Y, Arai H, Ogasawara K, Ogawa A. Change of oxygen pressure in glioblastoma tissue under various conditions. J Neurooncol. 2002; 58(1):47-52. Epub 2002/08/06. PMID: 12160140.
44. Kohshi K, Kinoshita Y, Imada H, Kunugita N, Abe H, Terashima H, et al. Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Br J Cancer. 1999; 80(1-2):236-41. Epub 1999/07/02. doi: 10.1038/sj.bjc.6690345 PMID: 10390002; PubMed Central PMCID: PMC2363018.
45. Becker A, Kuhnt T, Liedtke H, Krivokuca A, Bloching M, Dunst J. Oxygenation measurements in head and neck cancers during hyperbaric oxygenation. Strahlenther Onkol. 2002; 178(2):105-8. Epub 2002/04/11. PMID: 11942033.
46. Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer-a review. Targeted oncology. 2012; 7:233-42. Epub 2012/10/12. doi: 10.1007/s11523-012-0233-x PMID: 23054400.
47. Stuhr L, Raa A, Oyan A, Kalland K, Sakariassen P, Petersen K, et al. Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. J Neurooncol. 2007; 85:191-393. doi: 10.1007/s11060-007-9407-2 PMID: 17557137
48. Stuhr L, Iversen V, Straume O, Maehle B, Reed R. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer letters. 2004; 210:35-75. doi: 10.1016/j.canlet.2004.02.012 PMID: 15172118
49. Moen I, Tronstad K, Kolmannskog O, Salvesen G, Reed R, Stuhr L. Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. BMC Cancer. 2009; 9:446. doi: 10.1186/1471-2407-9-446 PMID: 20017908
50. Raa A, Stansberg C, Steen V, Bjerkvig R, Reed R, Stuhr L. Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer. 2007; 7:23. doi: 10.1186/1471-2407-7-23 PMID: 17263869
51. Daruwalla J, Christophi C. Hyperbaric oxygen therapy for malignancy: a review. World journal of surgery. 2006; 30:2112-43. doi: 10.1007/s00268-006-0190-6 PMID: 17102915
52. Al-Waili NS, Butler GJ, Beale J, Hamilton RW, Lee BY, Lucas P. Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med Sci Monit. 2005; 11(9):RA279-89. Epub 2005/08/30. PMID: 16127374.
53. Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. International journal of cancer. 2008; 123(1):73-84. Epub 2008/04/10. doi: 10.1002/ijc.23492 PMID: 18398829.
54. Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012; 18(20):5585-94. Epub 2012/10/17. doi: 10.1158/1078-0432.CCR-12-0858 PMID: 23071360.
55. Lim E, Modi KD, Kim J. In vivo bioluminescent imaging of mammary tumors using IVIS spectrum. J Vis Exp. 2009;(26:). Epub 2009/05/01. doi: 10.3791/1210 PMID: 19404236; PubMed Central PMCID: PMC2794084.
56. D'Agostino D, Putnam R, Dean J. Superoxide (∗O2-) production in CA1 neurons of rat hippocampal slices exposed to graded levels of oxygen. Journal of neurophysiology. 2007; 98:1030-71. doi: 10.1152/jn.01003.2006 PMID: 17553943
57. Huysentruyt LC, Shelton LM, Seyfried TN. Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. Int J Cancer. 2010; 126(1):65-72. Epub 2009/06/19. doi: 10.1002/ijc.24649 PMID: 19536778.
58. Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int J Cancer. 2010; 127(10):2478-85. Epub 2010/05/18. doi: 10.1002/ijc.25431 PMID: 20473919; PubMed Central PMCID: PMC2946425.
59. Shelton LM, Mukherjee P, Huysentruyt LC, Urits I, Rosenberg JA, Seyfried TN. A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol. 2010; 99(2):165-76. Epub 2010/01/14. doi: 10.1007/s11060-010-0115-y PMID: 20069342.
60. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013; 67(8):789-96. Epub 2013/06/27. doi: 10.1038/ejcn.2013.116 PMID: 23801097; PubMed Central PMCID: PMC3826507.
61. Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Dev Med Child Neurol. 2006; 48(12):978-81. Epub 2006/11/18. doi: 10.1017/S0012162206002143 PMID: 17109786.
62. Thom S. Hyperbaric oxygen: its mechanisms and efficacy. Plastic and reconstructive surgery. 2011; 127 Suppl 1. doi: 10.1097/PRS.0b013e3181fbe2bf
63. Gill AL, Bell CNA. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM. 2004; 97. doi: 10.1093/qjmed/hch074
64. Clarke K, Tchabanenko K, Pawlosky R, Carter E, Knight NS, Murray AJ, et al. Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. Regul Toxicol Pharmacol. 2012; 63(2):196-208. Epub 2012/04/17. doi: 10.1016/j.yrtph.2012.04.001 PMID: 22504461.
65. Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012; 63(3):401-8. Epub 2012/05/09. doi: 10.1016/j.yrtph.2012.04.008 PMID: 22561291.
66. Kashiwaya Y, Bergman C, Lee JH, Wan R, King MT, Mughal MR, et al. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013; 34(6):1530-9. Epub 2013/01/02. doi: 10.1016/j.neurobiolaging.2012.11.023 PMID: 23276384; PubMed Central PMCID: PMC3619192.
67. D'Agostino D, Pilla R, Held H, Landon CS, Ari C, Arnold P, et al. Development and testing of ketone esters for prevention of CNS oxygen toxicity seizures. Third International Symposium on Dietary Therapies for Epilepsy & Other Neurological Disorders; Chicago, IL2012.
68. D'Agostino DP, Pilla R, Held HE, Landon CS, Puchowicz M, Brunengraber H, et al. Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats. Am J Physiol Regul Integr Comp Physiol. 2013. Epub 2013/04/05. doi: 10.1152/ajpregu.00506.2012 PMID: 23552496.
69. Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging. 2012; 33(2):425 e19-27. Epub 2010/12/07. doi: 10.1016/j.neurobiolaging.2010.10.006 PMID: 21130529; PubMed Central PMCID: PMC3116949.
70. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol. 2006; 17(5-6):431-9. Epub 2006/08/31. PMID: 16940764; PubMed Central PMCID: PMC2367001.
71. Cahill GF Jr., Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc. 2003; 114:149-61; discussion 62-3. Epub 2003/06/20. PMID: 12813917; PubMed Central PMCID: PMC2194504.
72. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, leukotrienes, and essential fatty acids. 2004; 70(3):309-19. Epub 2004/02/11. doi: 10.1016/j.plefa.2003.09.007 PMID: 14769489.
73. Moen I, Øyan A, Kalland K-H, Tronstad K, Akslen L, Chekenya M, et al. Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One. 2009; 4. doi: 10.1371/journal.pone.0006381
74. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of Caloric Restriction, Ketogenic Diet and Intermittent Fasting during Initiation, Progression and Metastasis of Cancer in Animal Models: A Systematic Review and Meta-Analysis. PLoS One. 2014; 9(12):e115147. doi: 10.1371/journal.pone.0115147 PMID: 25502434; PubMed Central PMCID: PMC4263749.
75. Kesl S, Poff, A., Ward, N., Fiorelli, T., Ari, C., D'Agostino, D., editor Methods of sustaining dietary ketosis in Sprague-Dawley rats. Federation of the American Societies for Experimental Biology; 2014; San Diego, CA.
76. Boveris A, Costa LE, Poderoso JJ, Carreras MC, Cadenas E. Regulation of mitochondrial respiration by oxygen and nitric oxide. Ann N Y Acad Sci. 2000; 899:121-35. Epub 2000/06/23. PMID: 10863534.
77. Peleg RK, Fishlev G, Bechor Y, Bergan J, Friedman M, Koren S, et al. Effects of hyperbaric oxygen on blood glucose levels in patients with diabetes mellitus, stroke or traumatic brain injury and healthy volunteers: a prospective, crossover, controlled trial. Diving Hyperb Med. 2013; 43(4):218-21. Epub 2014/02/11. PMID: 24510327.
78. Al-Waili NS, Butler GJ, Beale J, Abdullah MS, Finkelstein M, Merrow M, et al. Influences of hyperbaric oxygen on blood pressure, heart rate and blood glucose levels in patients with diabetes mellitus and hypertension. Archives of medical research. 2006; 37(8):991-7. doi: 10.1016/j.arcmed.2006.05.009 PMID: 17045116.
79. Dedov II, Lukich VL, Bol'shakova TD, Gitel EP, Dreval AV. Effect of hyperbaric oxygenation on residual insulin secretion in patients with diabetes mellitus type 1. Probl Endokrinol (Mosk). 1987; 33(4):10-5. Epub 1987/07/01. PMID: 3309933.
80. Contreras FL, Kadekaro M, Eisenberg HM. The effect of hyperbaric oxygen on glucose utilization in a freeze-traumatized rat brain. J Neurosurg. 1988; 68(1):137-41. Epub 1988/01/01. doi: 10.3171/jns.1988.68.1.0137 PMID: 3335899.
81. Torbati D. Central nervous system glucose utilization rate during oxygen-induced respiratory changes at 2 atmospheres oxygen in the rat. J Neurol Sci. 1986; 76(2-3):231-7. Epub 1986/12/01. PMID: 3794751.
82. Bassett DJ, Fisher AB. Glucose metabolism in rat lung during exposure to hyperbaric O2. J Appl Physiol Respir Environ Exerc Physiol. 1979; 46(5):943-9. Epub 1979/05/01. PMID: 468612.
83. Schoen PJ, Raghoebar GM, Bouma J, Reintsema H, Vissink A, Sterk W, et al. Rehabilitation of oral function in head and neck cancer patients after radiotherapy with implant-retained dentures: effects of hyperbaric oxygen therapy. Oral oncology. 2007; 43(4):379-88. Epub 2006/09/26. doi: 10.1016/j.oraloncology.2006.04.009 PMID: 16996783.
84. Schumacker P. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer cell. 2006; 10:175-81. doi: 10.1016/j.ccr.2006.08.015 PMID: 16959608
85. Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008; 7(12):1875-84. Epub 2008/11/05. PMID: 18981733.
86. Aykin-Burns N, Ahmad I, Zhu Y, Oberley L, Spitz D. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. The Biochemical journal. 2009; 418:29-66. doi: 10.1042/bj20081258 PMID: 18937644
87. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci. 2000; 899:349-62. Epub 2000/06/23. PMID: 10863552.
88. Tonorezos ES, Jones LW. Energy balance and metabolism after cancer treatment. Semin Oncol. 2013; 40(6):745-56. Epub 2013/12/18. doi: 10.1053/j.seminoncol.2013.09.011 PMID: 24331194; PubMed Central PMCID: PMC3867745.
89. Feldmeier JJ. Hyperbaric oxygen therapy and delayed radiation injuries (soft tissue and bony necrosis): 2012 update. Undersea Hyperb Med. 2012; 39(6):1121-39. Epub 2013/01/25. PMID: 23342770.
90. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. IUBMB Life. 2001; 51(4):241-7. Epub 2001/09/25. doi: 10.1080/152165401753311780 PMID: 11569918.
91. Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer & metabolism. 2014; 2:18. doi: 10.1186/2049-3002-2-18 PMID: 25228990; PubMed Central PMCID: PMC4165433.
92. Allen BG, Bhatia SK, Buatti JM, Brandt KE, Lindholm KE, Button AM, et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013; 19(14):3905-13. Epub 2013/06/08. doi: 10.1158/1078-0432.CCR-12-0287 PMID: 23743570; PubMed Central PMCID: PMC3954599.
93. Abdelwahab M, Fenton K, Preul M, Rho J, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012; 7. doi: 10.1371/journal.pone.0036197
94. Marsh J, Mukherjee P, Seyfried T. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr Metab (Lond). 2008; 5:33. doi: 10.1186/1743-7075-5-33 PMID: 19032781
95. Hutton JL, Martin L, Field CJ, Wismer WV, Bruera ED, Watanabe SM, et al. Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. The American journal of clinical nutrition. 2006; 84(5):1163-70. Epub 2006/11/10. PMID: 17093170.
96. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. Journal of neuro-oncology. 2014; 117(1):125-31. Epub 2014/01/21. doi: 10.1007/s11060-014-1362-0 PMID: 24442482.
97. Wu GY, Thompson JR. The effect of ketone bodies on alanine and glutamine metabolism in isolated skeletal muscle from the fasted chick. The Biochemical journal. 1988; 255(1):139-44. Epub 1988/10/01. PMID: 2904261; PubMed Central PMCID: PMC1135201.
98. Manninen AH. Very-low-carbohydrate diets and preservation of muscle mass. Nutr Metab (Lond). 2006; 3:9. Epub 2006/02/02. doi: 10.1186/1743-7075-3-9 PMID: 16448570; PubMed Central PMCID: PMC1373635.
99. Cahill G. Fuel metabolism in starvation. Annual review of nutrition. 2006; 26:1-22. doi: 10.1146/annurev.nutr.26.061505.111258 PMID: 16848698
100. Volek J, Sharman M, Love D, Avery N, Gómez A, Scheett T, et al. Body composition and hormonal responses to a carbohydrate-restricted diet. Metabolism: clinical and experimental. 2002; 51(7):864-70. doi: 10.1053/meta.2002.32037 PMID: 12077732
101. Paoli A, Grimaldi K, D'Agostino D, Cenci L, Moro T, Bianco A, et al. Ketogenic diet does not affect strength performance in elite artistic gymnasts. Journal of the International Society of Sports Nutrition. 2012; 9(1):34. doi: 10.1186/1550-2783-9-34 PMID: 22835211
102. Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. The American journal of clinical nutrition. 1988; 47(1):42-8. Epub 1988/01/01. PMID: 3122552.
103. Mulligan HD, Tisdale MJ. Metabolic substrate utilization by tumour and host tissues in cancer cachexia. The Biochemical journal. 1991; 277 (Pt 2):321-6. Epub 1991/07/15. PMID: 1859359; PubMed Central PMCID: PMC1151235.
104. Bennewith K, Dedhar S. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer. 2011; 11:504. doi: 10.1186/1471-2407-11-504 PMID: 22128892
105. Bennett M, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy: a systematic review of randomised controlled trials. Cancer treatment reviews. 2008; 34(7):577-91. doi: 10.1016/j.ctrv.2008.01.001 PMID: 18640781